Summary
The pathophysiological mechanisms involved in the development of a spontaneous systemic capillary leak syndrome (CLS) are unknown. In contrast, CLS is a well-known side effect of high-dose interleukin-2 (IL-2) therapy in solid tumors. We report on a patient who developed CLS with high serum levels of endogenous IL-2 under immunosuppressive therapy for chronic graft-versus-host disease (GvHD) after allogeneic bone marrow transplantation (BMT). Generalized edema persisted for 10 weeks. The condition resolved after antibiotic therapy of a septic shock withβ hemolyzing streptococci group A. Thus, a latent infection may alter cytokine homeostasis and may cause CLS in BMT patients.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Belosevic M, Finbloom DS, Meltzer MS, Nacy CA (1990) IL-2 — a cofactor for induction of activated macrophage resistance to infection. J Immunol 145:831–839
Cahill RA, Zhao Y, Murphy R, Sala A, Foegh M, Spitzer T, Deeg HJ (1990) High urinary leukotriene E4 (LTE4) and thromboxane 2 (TxB2) levels are associated with capillary leak syndrome in bone marrow transplant patients. Adv Prostaglandin Thromboxane Leukotriene Res 21:525–528
Clarkson B, Thompson D, Horwith M, Luckey HE (1960) Cyclical edema and shock due to increased capillary permeability. Am J Med 29:193–216
Cone LA, Woodward DR, Schlievert PM, Tomory GS (1987) Clinical and bacteriological observations of a toxic shock-like syndrome due toStreptococcus pyogenes. N Engl J Med 317:146–149
Damle NK, Doyle LV (1989) IL-2 activated human killer lymphocytes but not their secreted products mediate increase in albumin flux across cultured endothelial monolayers. J Immunol 142:2660–2669
Fast DJ, Schlievert PM, Nelson RD (1989) Toxic shock syndrome-associated staphylococcal and streptococcal pyrogenic toxins are potent inducers of tumor necrosis factor production. Infect Immunol 57:291–294
Gallagher G, Willdridge J (1988) Evidence that interleukin-2 actively promotes both cell division and immunoglobulin secretion in human B cells. Int Arch Allergy Immunol 86:337–342
Gallati H, Brockhaus M (1992) Detection of human soluble TNF receptors in biological fluids. Eur Cytokine Netw 3:264
Guerne P-A, Carson DA, Lotz M (1990) IL-6 production by human articular chondrocytes. Modulation of its synthesis by cytokines, growth factors and hormones in vitro. J Immunol 144:499–505
Maestracci P, Benoit P, Dupeyrat J, Maiolini R (1981) Choc hypovolémique par augmentation de la permeabilité capillaire. Nouv Presse Med 10:329–330
Michie HR, Guillou PJ, Wilmore DW (1989) Tumor necrosis factor and bacterial sepsis. Br J Surg 76:670–671
Miethke T, Duschek K, Wahl C, Heeg K, Wagner H (1993) Pathogenesis of the toxic shock syndrome: T-cell-mediated lethal shock caused by superantigen TSST-1. Eur J Immmunol 23:1494–1500
Murray HW (1988) Interferon-gamma, the activated macrophage and host defense against microbial challenge. Ann Intern Med 108:595–608
Ohkubo C, Bigos D, Jain RK (1991) Interleukin-2 induces leukocyte adhesion to the normal and tumor microvascular endothelium in vivo and its inhibition by dextran sulfate: implications for the vascular leak syndrome. Cancer Res 51:1561–1563
Przepiorka D, Shapiro S, Schwinghammer TL, Bloom EJ, Rosenfeld CS, Shadduck RK, Venkataramanan R (1991) Cyclosporin and methylprednisolone after allogenic marrow transplantation: association between low cyclosporin concentration and risk of acute graft-versus-host disease. Bone Marrow Transplant 7:461–465
Rosenberg SA, Lotze MT, Muul LM, Chang AE, Avis FP, Leitman S, Linehan WM, Robertson GN, Lee RE, Rubin JT, Scipp CA, Simpson CG, White DE (1987) A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 316:889–897
Rosenstein M, Ettinghausen SE, Rosenberg SA (1986) Extravasation of intravascular fluid mediated by the systemic administration of recombinant interleukin-2. J Immunol 137:1735–1742
Teelucksingh S, Padfield PL, Edwards CRW (1990) Systemic capillary leak syndrome. Q J Med 277:515–524
Tosato G, Jones KD (1990) Interleukin-1 induces interleukin-6 production in human peripheral blood monocytes. Blood 75:1305–1310
Uchiyama T, Kayamata Y, Yan XJ, Kohno M, Yoshioka M, Fujikawa H, Igavashi H, Okubo M, Awano F, Saito-Taki T, Nakano M (1987) Study of the biologic activities of toxic shock syndrome toxin-1. II. Induction of the proliferative response and the interleukin-2 production by T cells from human peripheral blood mononuclear cells stimulated with the toxin. Clin Exp Immunol 68:638–647
Vetto JT, Papa MZ, Lotze MT, Chang AE, Rosenberg SA (1987) Reduction of toxicity of interleukin-2 and lymphokine-activated killer cells in humans by the administration of corticosteroids. J Clin Oncol 5:496–503
Waage A, Brandtzaeg P, Haltensen A, Kienuff P, Espevik T (1989) The complex pattern of cytokines in serum from patients with meningococcal septic shock. J Exp Med 169:333–338
Willoughby R, Greenberg RN (1983) The toxic shock syndrome and streptococcal pyrogenic exotoxins. Ann Intern Med 98:559
Zuckerman SH, Shellhaas J, Butler LD (1989) Differential regulation of lipopolysaccharide-induced interleukin-1 and tumor necrosis factor synthesis: effects of endogenous and exogenous glucocorticoids and the role of the pituitary-adrenal axis. Eur J Immunol 19:301–305
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Funke, L., Prümmer, O., Schrezenmeier, H. et al. Capillary leak syndrome associated with elevated IL-2 serum levels after allogeneic bone marrow transplantation. Ann Hematol 68, 49–52 (1994). https://doi.org/10.1007/BF01695920
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01695920